Adelaide, South Australia wants to let the secret out, and be known as hub for medical devices, pharmaceuticals, biotechnology, and digital health. It boasts world-class research institutions, such as the University of Adelaide and SAHMRI, fostering innovation and collaboration. The city’s supportive government policies provide incentives, grants, and streamlined regulations for businesses. Adelaide’s skilled workforce, renowned for its expertise in health sciences, offers a talent pool to drive industry growth. Additionally, the city’s strategic location, advanced infrastructure, and strong healthcare ecosystem make it an ideal base for development, manufacturing, and market access, attracting companies in these sectors.
Australian Health Journal spoke to Jo Close, heading the Adelaide arm of MTPConnect about the opportunity its building through its role as the industry growth centre, to help increase commercialisation and collaboration across the sector, optimise the regulatory environment, improving workforce skills and access to markets globally.
One of the companies showing world leading MedTech capabilities arising from Adelaide is Additive Surgical, the first company in Australia to manufacture 3D Printed Titanium novel spinal implant technologies. Its mission is to manufacture the highest quality medical technology in Australia that positively impact the lives of people globally.
Australian Health Journal met with Co-founder and CEO Gibran Maher.
Maher states, “Additive Surgical is committed to supporting Australian innovation and works closely with the Australian clinicians, hospitals, research institutions and universities to innovate and manufacture locally.”
Maher points out the ability to compete is made possible through supportive collaboration with government, research and other enterprises seeking to learn from each other. But to truely compete in international markets, Australia’s needs to further strengthen its sovereign capability.
Currently Australia imports more than 80% of its medical devices. Large multinational companies have very strong market share in Australia and the profits from these companies are largely returned to their international shareholders.
Additive Surgical is committed to manufacturing in Australia, developing intellectual property in Australia and supporting Australian innovation and commercialisation.
-
Evolution of the pharmacy tribe
The past 18 months has shown the strength of Australian pharmacies in ensuring accessibility, credibility and maintaining rapport with the community to administer COVID-19 vaccinations, handle electronic prescriptions and looking to play an integrated role in aged care.
-
Australian Healthcare Week 2019: Pitch Fest Finalist Coviu
Telelheath startup company Coviu was a Pitch Fest Finalist at last week’s Australian Healthcare Week Expo in Sydney. The Coviu platform has been developed as an spinoff from CSIRO and allows healthcare businesses offer video consultations to their own patients. It differs from being just a ‘talking head’ platform that Skype or Zoom could offer, by providing clinical tools integrated within the app. Anne Dao spoke with Co-founder and CEO Silvia Pfeiffer about the company and platform’s journey to date and its longer term goals.
Coviu helps healtcare businesses by helping fit in more consultation during that day and reducing no-shows for appointments. Also given the nature of the dispersed population, the application reaches to rural and regional areas where patients are a long distance from their healthcare provider. The company is focused on the Australian market and aims to enter the US market next year
-
Improved treatment in advanced-stage Hodgkin lymphoma
A global clinical trial successfully reduced toxicity and side effects in advanced stage Hodgkin lymphoma patients by using a modified treatment regimen.
Australian Health Journal spoke with Professor Mark Hertzberg in his role in the ALLG HD10 Clinical Trial and as a former Chair of the Scientific Advisory Committee of the Australasian Leukaemia & Lymphoma Group (ALLG), an organisation involved in improving the treatments and lives of blood cancer patients.
